Gilead Sees Room For Trodelvy In European Markets
Triple-Negative Breast Cancer Claim Clears CHMP
Executive Summary
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
You may also be interested in...
Gilead Awaits EMA Verdict On Trodelvy As It Whizzes Through EU Review
Sponsors of six new products, including a first-in-class treatment for unresectable locally advanced or metastatic triple-negative breast cancer, will find out this week if their products are on course to be approved for use in the EU. Also, two sponsors might be asked to address last-minute questions about their drugs.
Gilead Builds Up Trodelvy Data In TNBC Ahead Of Competition
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer
While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.